{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:29:49Z","timestamp":1771651789593,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T00:00:00Z","timestamp":1536796800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00428-018-2453-7","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T18:27:29Z","timestamp":1536776849000},"page":"719-724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer"],"prefix":"10.1007","volume":"473","author":[{"given":"Larisa","family":"Zavalishina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilya","family":"Tsimafeyeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrisia","family":"Povilaitite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grigory","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia","family":"Andreeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Petrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Kharitonova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Rumyantsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Pugach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgy","family":"Frank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergei","family":"Tjulandin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,13]]},"reference":[{"key":"2453_CR1","unstructured":"Ferlay, J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012v1.0, cancer incidence and mortality worldwide. IARC Cancer Base No. 11. [Internet]. Lyon, France: International Agency for Research on Cancer \n                    http:\/\/globocan.iarc.fr\n                    \n                   accessed on 04 April 2018"},{"key":"2453_CR2","unstructured":"Kaprin A, Starinskiy V, Petrova G. Malignant tumors in Russia in 2012 (morbidity and mortality). Moscow. 2012. p.250. ISBN ISBN 978-5-85502-193-6"},{"issue":"suppl_3, 1","key":"2453_CR3","doi-asserted-by":"publisher","first-page":"iii40","DOI":"10.1093\/annonc\/mdu223","volume":"25","author":"J Bellmunt","year":"2014","unstructured":"Bellmunt J, Orsola A, Leow JJ, Wiegel T, de Santis M, Horwich A, on behalf of the ESMO Guidelines Working Group (2014) Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(suppl_3, 1):iii40\u2013iii48","journal-title":"Ann Oncol"},{"issue":"21","key":"2453_CR4","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H Maase von der","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23(21):4602\u20134608","journal-title":"J Clin Oncol"},{"issue":"7","key":"2453_CR5","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","volume":"10","author":"PJ Loehrer Sr","year":"1992","unstructured":"Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10(7):1066\u20131073","journal-title":"J Clin Oncol"},{"issue":"17","key":"2453_CR6","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H Maase von der","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068\u20133077","journal-title":"J Clin Oncol"},{"key":"2453_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","volume":"54","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, Powles T, Vogelzang NJ (2017) A review on the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev 54:58\u201367","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"2453_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF, KEYNOTE-045 Investigators (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015\u20131026","journal-title":"N Engl J Med"},{"issue":"10122","key":"2453_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS, Loriot Y, Vogelzang NJ, de Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Fl\u00e9chon A, Gravis G, Hussain S, Takano T, Leng N, Kadel EE III, Banchereau R, Hegde PS, Mariathasan S, Cui N, Shen X, Derleth CL, Green MC, Ravaud A (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391(10122):748\u2013757","journal-title":"Lancet"},{"issue":"9","key":"2453_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"T Powles","year":"2017","unstructured":"Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM (2017) Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study. JAMA Oncol 3(9):e172411","journal-title":"JAMA Oncol"},{"issue":"2_suppl","key":"2453_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1200\/jco.2016.34.2_suppl.355","volume":"34","author":"JH Hoffman-Censits","year":"2016","unstructured":"Hoffman-Censits JH, Grivas P, Van Der Heijden MS et al (2016) IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). J Clin Oncol 34(2_suppl):355\u2013355","journal-title":"J Clin Oncol"},{"issue":"3","key":"2453_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz J\u00c1, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18(3):312\u2013322","journal-title":"Lancet Oncol"},{"issue":"14","key":"2453_CR13","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1158\/1078-0432.CCR-16-2375","volume":"23","author":"MJ Ratcliffe","year":"2017","unstructured":"Ratcliffe MJ, Sharpe A, Midha A, Barker C, Scott M, Scorer P, al-Masri H, Rebelatto MC, Walker J (2017 Jul 15) Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non\u2013small cell lung cancer. Clin Cancer Res 23(14):3585\u20133591","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2453_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM (2017) PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol 12(2):208\u2013222","journal-title":"J Thorac Oncol"},{"issue":"Issue suppl_5","key":"2453_CR15","first-page":"mdx376.040","volume":"28","author":"K Schwamborn","year":"2017","unstructured":"Schwamborn K, Kn\u00fcchel R, Hartmann A et al (2017) Comparability of programmed death-ligand 1 (PD-L1) expression on tumor-infiltrating immune cells (IC) and tumor cells (TC) in advanced urothelial bladder cancer (UBC) using clinically relevant immunohistochemistry (IHC) assays. Ann Oncol 28(Issue suppl_5):mdx376.040","journal-title":"Ann Oncol"},{"key":"2453_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/modpathol.2017.188","volume":"31","author":"M Tretiakova","year":"2017","unstructured":"Tretiakova M, Fulton R, Kocherginsky M, Long T, Ussakli C, Antic T, Gown A (2017) Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. Mod Pathol 31:623\u2013632. \n                    https:\/\/doi.org\/10.1038\/modpathol.2017.188","journal-title":"Mod Pathol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-018-2453-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T06:46:55Z","timestamp":1569048415000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-018-2453-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,13]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2453"],"URL":"https:\/\/doi.org\/10.1007\/s00428-018-2453-7","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,13]]},"assertion":[{"value":"22 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the study has been done according to ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}